Navigation Links
Patients’ Immune System May Influence Immunotherapy
Date:4/2/2017

Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute (UPCI).

The findings will be presented today at the American Association of Cancer Research (AACR) Annual Meeting in Washington, D.C., by Robert Ferris, M.D., Ph.D., UPMC Endowed Professor, chief of the Division of Head and Neck Surgery, and co-leader of the Cancer Immunology Program at UPCI.

The research was an extension of the recently completed CheckMate 141 Phase III clinical trial co-chaired by Dr. Ferris, which showed that the immunotherapy nivolumab significantly increases survival and causes fewer adverse side effects in patients with recurrent head and neck cancer.

However, the treatment was not equally effective in all the patients so Dr. Ferris and his team aimed to find out whether differences in the patients’ immune system profiles could be associated with better response to immunotherapy.

The researchers found that higher levels of tumor-associated immune cells (TAICs) expressing the PD-L1 protein were associated with longer overall survival and greater likelihood of response to the drug nivolumab. TAICs are immune cells that have infiltrated the tumor and are thought to play an important role in tumor growth.

In blood samples taken prior to the start of immunotherapy, the researchers also found that patients with higher levels of circulating CD8, or cytotoxic, T cells—also known as killer T cells—and lower levels of regulatory T cells were associated with better response to treatment.

“Our study shows that immune cells in the microenvironment around the tumor could play a critical role in how patients respond to immunotherapy. By determining the nature of these cells and how they are affected by treatments, we may be able to significantly improve the effectiveness of current therapies and help a greater number of patients,” said Dr. Ferris.

Additional U.S. institutions that participated in the CheckMate trial include Ohio State University, University of Texas MD Anderson Cancer Center, Stanford Cancer Institute, University of Chicago, Dana-Farber Cancer Institute and Bristol-Myers Squibb.

International collaborators are located at BC Cancer Agency in Canada; Centre Leon Berard, Centre Antoine Lacassagne, and Institut Gustave Roussy, all in France; Fondazione IRCCS Istituto Nazionale Tumori, and University of Milan in Italy; The Institute of Cancer Research, in the United Kingdom; University Hospital Essen, in Germany; Hospital Universitario 12 de Octubre, in Spain; University Hospital Zurich, in Switzerland; and National Cancer Center Hospital East in Japan.

This study was funded by UPCI and Bristol-Myers Squibb.

Read the full story at http://www.prweb.com/releases/2017/04/prweb14204710.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Physicians ‘Like’ Patients’ Efforts to Self-Educate Online, Notes Dr. Shirin Towfigh
2. NY Breast Reconstruction Associates Honor Patients’ Journeys at The Uplifting Event
3. Get Real Health’s CHBase™ Gives Healthcare Providers a 360° View of Patients’ Health
4. Patients’ Healthcare Partners Celebrated During National Case Management Week
5. 449 Recovery Joins the MAP Recovery Network to Track Outcomes Data and Improve Patients’ Long-term Recovery Rates
6. Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act
7. North Shore-LIJ Completes Last Phase of $50M Upgrade of its Diagnostic Imaging Systems, $12M for GE Low-Dose CT Scanners to Reduce Patients’ Radiation Exposure
8. University of Colorado Cancer Center Study Shows How to Keep Nanoparticle Caterpillars Safe From the Crows of the Immune System
9. Introducing Zen Air Immune Boost Diffuser Blend of Essential Oils, Joining the Popular Topical Blend from Sublime Naturals for Wellness.
10. Advanced Cell Diagnostics Webinar on Surveying Expression of Immune Checkpoint Markers in Tissue Microenvironment
11. Chronic Inflammation of Obesity, Autoimmune Conditions Leads to Imbalanced Blood System and Potential Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... In a ... PlushBeds , a luxury online mattress company that specializes in natural and organic ... nation’s leading grassroots autism organization) for every unique share their recent viral Facebook ...
(Date:5/19/2017)... ... May 19, 2017 , ... DMG Productions is ... of Innovations with Ed Begley, Jr., airing fourth quarter 2017 on FOX Business. ... clean, organic dietary supplement made from naturally occurring ingredients. Innovations will enlighten viewers ...
(Date:5/19/2017)... ... 2017 , ... Springfield, Vermont-based law firm of Brady/Callahan has released a new ... Hire An Experienced Personal Injury Attorney, " the article offers insight for people who ... article says. if someone is injured due to another person's negligence, they ...
(Date:5/19/2017)... ... May 19, 2017 , ... The ... planning assistance to families and business owners in the region, is embarking on ... MS sufferers and their families. , Multiple sclerosis (MS) is a demyelinating disease ...
(Date:5/19/2017)... Reston, VA (PRWEB) , ... May 19, 2017 ... ... mobile application containerization, today announced a sponsorship and speaking session at the 7th ... Exchange is the longest-running hosted enterprise mobility and digital transformation conference whose expressed ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
Breaking Medicine Technology: